To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Mesna
Mesna (INN) (pronounced /ˈmɛznə/) is an adjuvant used in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is currently marketed by Baxter as Uromitexan® and Mesnex®. Additional recommended knowledgeMesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as acrolein. Mesna assists to neutralise these metabolites by binding through its sulfhydryl-moieties, and also increases urinary excretion of cysteine.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mesna". A list of authors is available in Wikipedia. |